Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day
Capricor Therapeutics (NASDAQ: CAPR) announced its participation in the 2025 Piper Sandler Virtual Cardio Day on April 2, 2025. CEO Linda Marbán will lead a fireside chat from 12:00-12:30 p.m. ET to discuss updates on deramiocel, their lead program for treating Duchenne muscular dystrophy (DMD).
Deramiocel, an allogeneic cardiac-derived cell therapy, has demonstrated immunomodulatory and anti-fibrotic properties in preserving cardiac and skeletal muscle function in dystrophiopathies. The company is also developing its proprietary StealthX™ platform for exosome technology applications in vaccinology and targeted therapeutic delivery.
Capricor has secured an exclusive commercialization and distribution agreement with Nippon Shinyaku Co., for deramiocel in the United States and Japan, pending regulatory approval.
Capricor Therapeutics (NASDAQ: CAPR) ha annunciato la sua partecipazione al 2025 Piper Sandler Virtual Cardio Day il 2 aprile 2025. L'amministratore delegato Linda Marbán condurrà una conversazione informale dalle 12:00 alle 12:30 ET per discutere gli aggiornamenti su deramiocel, il loro programma principale per il trattamento della distrofia muscolare di Duchenne (DMD).
Deramiocel, una terapia cellulare derivata dal cuore allogenico, ha dimostrato proprietà immunomodulatorie e anti-fibrotiche nel preservare la funzione cardiaca e muscolare scheletrica nelle distrofie. L'azienda sta anche sviluppando la sua piattaforma proprietaria StealthX™ per applicazioni tecnologiche di esosoma in vaccinologia e somministrazione terapeutica mirata.
Capricor ha ottenuto un accordo esclusivo di commercializzazione e distribuzione con Nippon Shinyaku Co. per deramiocel negli Stati Uniti e in Giappone, in attesa di approvazione normativa.
Capricor Therapeutics (NASDAQ: CAPR) anunció su participación en el 2025 Piper Sandler Virtual Cardio Day el 2 de abril de 2025. La CEO Linda Marbán liderará una charla informal de 12:00 a 12:30 p.m. ET para discutir las actualizaciones sobre deramiocel, su programa principal para el tratamiento de la distrofia muscular de Duchenne (DMD).
Deramiocel, una terapia celular derivada del corazón alogénica, ha demostrado propiedades inmunomoduladoras y antifibróticas para preservar la función cardíaca y muscular esquelética en distrofias. La empresa también está desarrollando su plataforma propietaria StealthX™ para aplicaciones de tecnología de exosomas en vacunología y entrega terapéutica dirigida.
Capricor ha asegurado un acuerdo exclusivo de comercialización y distribución con Nippon Shinyaku Co. para deramiocel en los Estados Unidos y Japón, sujeto a la aprobación regulatoria.
Capricor Therapeutics (NASDAQ: CAPR)는 2025년 4월 2일에 2025 Piper Sandler Virtual Cardio Day에 참여한다고 발표했습니다. CEO인 Linda Marbán이 오후 12시부터 12시 30분(ET)까지 deramiocel에 대한 업데이트를 논의하기 위해 대화 세션을 이끌 것입니다. 이는 Duchenne 근이영양증 (DMD) 치료를 위한 주요 프로그램입니다.
Deramiocel은 심장에서 유래한 동종 세포 치료제로, 근이영양증에서 심장 및 골격근 기능을 보존하는 면역 조절 및 항섬유화 특성을 보여주었습니다. 회사는 또한 백신학 및 표적 치료 전달을 위한 엑소좀 기술 응용을 위한 자사의 독점 StealthX™ 플랫폼을 개발하고 있습니다.
Capricor는 미국과 일본에서 deramiocel의 상업화 및 배급에 대한 독점 계약을 Nippon Shinyaku Co.와 체결했으며, 규제 승인을 기다리고 있습니다.
Capricor Therapeutics (NASDAQ: CAPR) a annoncé sa participation au 2025 Piper Sandler Virtual Cardio Day le 2 avril 2025. La PDG Linda Marbán dirigera une discussion informelle de 12h00 à 12h30 (ET) pour discuter des mises à jour concernant deramiocel, leur programme phare pour le traitement de la .
Deramiocel, une thérapie cellulaire allogénique dérivée du cœur, a démontré des propriétés immunomodulatrices et antifibrotiques pour préserver la fonction cardiaque et musculaire squelettique dans les dystrophies. L'entreprise développe également sa plateforme propriétaire StealthX™ pour des applications de technologie d'exosomes en vaccinologie et en délivrance thérapeutique ciblée.
Capricor a sécurisé un accord exclusif de commercialisation et de distribution avec Nippon Shinyaku Co. pour deramiocel aux États-Unis et au Japon, en attente d'une approbation réglementaire.
Capricor Therapeutics (NASDAQ: CAPR) hat seine Teilnahme am 2025 Piper Sandler Virtual Cardio Day am 2. April 2025 bekannt gegeben. CEO Linda Marbán wird von 12:00 bis 12:30 Uhr ET ein informelles Gespräch führen, um Updates zu deramiocel, ihrem Hauptprogramm zur Behandlung von Duchenne-Muskeldystrophie (DMD), zu diskutieren.
Deramiocel, eine allogene zelluläre Therapie, hat immunmodulatorische und antifibrotische Eigenschaften zur Erhaltung der Herz- und Skelettmuskel-Funktion bei Dystrophien gezeigt. Das Unternehmen entwickelt auch seine proprietäre StealthX™-Plattform für Anwendungen der Exosom-Technologie in der Impfstoffforschung und gezielten therapeutischen Abgabe.
Capricor hat einen exklusiven Vermarktungs- und Vertriebsvertrag mit Nippon Shinyaku Co. für deramiocel in den Vereinigten Staaten und Japan abgeschlossen, der auf die Genehmigung durch die Aufsichtsbehörden wartet.
- None.
- None.
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company will present at the 2025 Piper Sandler Virtual Cardio Day taking place on April 2, 2025.
Capricor will take part in a fireside chat to discuss the company’s latest advancements on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general regulatory, scientific and corporate updates.
Capricor Therapeutics Fireside Chat
- Date: Wednesday, April 2, 2025
- Time: 12:00–12:30 p.m. ET
- Participants: Linda Marbán, Ph.D., Chief Executive Officer
The Piper Sandler Virtual Cardio Day is an invitation-only event exclusive to Piper Sandler clients. For additional details or to request access to the webcast, please contact your PSC representative.
About Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel, an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to exert potent immunomodulatory and anti-fibrotic actions in preservation of cardiac and skeletal muscle function in dystrophiopathies such as DMD. Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, 2025. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug (IND) and is not yet approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
FAQ
What is the purpose of Capricor's presentation at the 2025 Piper Sandler Virtual Cardio Day?
How does Capricor's deramiocel treatment work for Duchenne muscular dystrophy?
What is the current development stage of CAPR's deramiocel for DMD treatment?
What territories are covered in CAPR's commercialization agreement for deramiocel?
What additional technologies is CAPR developing besides deramiocel?
